冠状动脉CTA检出动脉粥样硬化斑块患者预防性管理策略的指导:DECIDE注册研究主要结局
DECIDE前瞻性观察性前后对照研究纳入972例有斑块的症状性患者,延迟90天释放AI斑块分析结果以评估管理变化。AI-CPA结果可用后51.3%患者管理发生改变,斑块越广泛改变越常见(最高分期达67.8%,P<0.001),最常见为强化药物治疗(35.6%),管理改变者低密度脂蛋白胆固醇降幅更大。
要点
- AI斑块分析结果可用后51.3%患者管理改变,强化药物治疗最常见(35.6%)。
- 斑块越广泛管理改变越常见,最高分期达67.8%(P<0.001)。
- 管理改变者低密度脂蛋白胆固醇降幅大于无改变者(-11 mg/dL vs 1 mg/dL,P=0.002)。
核心结论
- DECIDE注册研究支持AI-CPA与预防性管理改变相关,尤其对斑块更广泛患者强化治疗;作者认为需开展随机试验探索AI-CPA的效用。
研究设计与样本
- DECIDE注册研究为前瞻性、观察性、前后对照干预子研究,纳入972例有动脉粥样硬化斑块的症状性患者,中位年龄64岁(Q1-Q3:56-72岁),女性占50.2%;AI-CPA结果延迟至索引冠状动脉CTA后90天释放给治疗医师,随后再随访90天。
诊断标准与关键数值
- 主要结局为AI-CPA后管理改变:调整预防/抗缺血治疗、新实验室检查、转诊专科或转诊负荷试验/有创冠状动脉造影。
- AI-CPA结果可用后51.3%(95%CI:48.2%-54.5%)的参与者发生管理改变。
- 斑块更广泛者管理改变更频繁,最高分期达67.8%(P<0.001)。
- 强化药物治疗是最常见的管理改变,发生于35.6%的参与者。
临床应用与阅片要点
- 作者认为AI-CPA与预防性管理改变相关,尤其对斑块更广泛患者强化治疗。
- 作者认为需开展随机试验探索AI-CPA的效用。
局限性
- 作者认为需开展随机试验探索AI-CPA的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Artificial intelligence-enabled coronary plaque analysis (AI-CPA) has been shown to improve cardiovascular risk prediction. However, little is known about how these measures influence management.
OBJECTIVES: This study sought to define changes in management guided by AI-CPA as compared with management guided by measures of nonobstructive and obstructive stenosis on coronary computed tomographic angiography (CTA) alone.
METHODS: The DECIDE (AI [Artificial Intelligence]-DErived Plaque Quantification: Coronary CTA and AI-QCPA [Artificial Intelligence-Derived Quantitative Coronary Plaque Analysis] for Determining Effective CAD [Coronary Artery Disease] Management) registry is a prospective, observational, pre-post interventional substudy. The substudy includes delayed release of AI-CPA findings to treating physicians until 90 days after the index coronary CTA, followed by an additional 90 days of follow-up. The primary outcome is change in management: modification of preventive/anti-ischemic therapies, new laboratory testing, referral to a specialist, or referral to stress testing/invasive coronary angiography post AI-CPA.
RESULTS: A total of 972 symptomatic patients with atherosclerotic plaque were enrolled (median age 64 years [Q1-Q3: 56-72 years], and 50.2% were women). Changes in management following the availability of AI-CPA occurred in 51.3% (95% CI: 48.2%-54.5%) of participants and were more frequent in patients with more extensive plaque (up to 67.8% in the highest stage; P < 0.001). Intensifying medical therapy was the most common management change, occurring in 35.6% of participants. Participants with management changes realized greater reductions in low-density lipoprotein cholesterol than did patients without these changes (-11 mg/dL [Q1-Q3: -42.5 to 4 mg/dL] vs 1 mg/dL [Q1-Q3: -18 to 14 mg/dL]; P = 0.002).
CONCLUSIONS: The DECIDE registry supports that AI-CPA was associated with preventive management changes, especially intensification of care for patients with more extensive plaque. Randomized trials to explore the utility of AI-CPA are warranted. (AI-DErived Plaque Quantification: Coronary CTA and AI-QCPA for Determining Effective CAD Management [DECIDE]; NCT06376851).
引用
- Rinehart S, Blankstein R, McCarthy CP, et al. Guiding Preventive Care Strategies for Patients With Atherosclerotic Plaque on Coronary CTA: Primary Outcomes of the DECIDE Registry. JACC Cardiovasc Imaging. 2026. PMID: 41817483. doi:10.1016/j.jcmg.2026.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。